About: The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Background There is minimal data about the efficacy of subsequent therapy in patients with relapse after FCR (fludarabine, cyclophosphamide, rituximab) chemoimmunotherapy. Methods We retrospectively analyzed the outcomes of 119 patients who relapsed after standard-dose FCR. The patient cohort consisted of patients who relapsed after FCR administered as first-line therapy (Group 1, n=63) and patients relapsing after FCR administered in second/subsequent line; (Group 2, n=56). Results Basic parameters (age, clinical stage, cytogenetics, molecular genetics) did not differ significantly between these subgroups. Likewise, median progression-free survival (PFS) was not considerably different after FCR (18.6 vs. 14.7 months). Subsequent therapy for relapsed disease included FCR retreatment, R-CHOP, alemtuzumab, or rituximab plus high-dose dexamethasone. Overall response rates for the two groups did not significantly differ (59% vs. 44%). Background There is minimal data about the efficacy of subsequent therapy in patients with relapse after FCR (fludarabine, cyclophosphamide, rituximab) chemoimmunotherapy. Methods We retrospectively analyzed the outcomes of 119 patients who relapsed after standard-dose FCR. The patient cohort consisted of patients who relapsed after FCR administered as first-line therapy (Group 1, n=63) and patients relapsing after FCR administered in second/subsequent line; (Group 2, n=56). Results Basic parameters (age, clinical stage, cytogenetics, molecular genetics) did not differ significantly between these subgroups. Likewise, median progression-free survival (PFS) was not considerably different after FCR (18.6 vs. 14.7 months). Subsequent therapy for relapsed disease included FCR retreatment, R-CHOP, alemtuzumab, or rituximab plus high-dose dexamethasone. Overall response rates for the two groups did not significantly differ (59% vs. 44%). (en)
Title	The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab (en)
skos:prefLabel	The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab (en)
skos:notation	RIV/00216224:14740/13:00065583!RIV14-MZ0-14740___
http://linked.open...avai/riv/aktivita	I P
http://linked.open...avai/riv/aktivity	I, P(ED1.1.00/02.0068), P(EE2.3.20.0045), P(FR-TI2/254), P(NT13412), P(NT13493), P(NT13519)
http://linked.open...iv/cisloPeriodika	6
http://linked.open...vai/riv/dodaniDat	2014
http://linked.open...aciTvurceVysledku	Lindtnerová, Michaela Pospíšilová, Šárka Brychtová, Yvona Doubek, Michael Mayer, Jiří Panovská, Anna Malčíková, Jitka Trbušek, Martin
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykova univerzita / Středoevropský technologický institut
http://linked.open...dnocenehoVysledku	94890
http://linked.open...ai/riv/idVysledku	RIV/00216224:14740/13:00065583
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	chronic lymhocytic leukemia; FRC chemoimmunotherapy; relapse; survival (en)
http://linked.open.../riv/klicoveSlovo	FRC chemoimmunotherapy chronic lymhocytic leukemia relapse survival
http://linked.open...odStatuVydavatele	DK - Dánské království
http://linked.open...ontrolniKodProRIV	[D3C18ED7A151]
http://linked.open...i/riv/nazevZdroje	European Journal of Haematology
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	8 (xsd:int)
http://linked.open...cetTvurcuVysledku	13 (xsd:int)
http://linked.open...vavai/riv/projekt	Molecular Characterization of B-cell Receptors and Their Relationship to Evolution of Gemonic Aberrations in Chronic Lymphocytic Leukemia Early identification of CLL patients with yet unselected p53 mutation *Real-time PCR kits for detection in oncology Central european institute of technology Support of Professional Growth and International Integration of Research Teams in the Filed of Molecular Medicine Complex assessment of microenvironment and its impact on clinical course of chronic lymphocytic leukemia.
http://linked.open...UplatneniVysledku	2013
http://linked.open...v/svazekPeriodika	90
http://linked.open...iv/tvurceVysledku	Brychtová, Yvona Doubek, Michael Mayer, Jiří Panovská, Anna Pospíšilová, Šárka Malčíková, Jitka Trbušek, Martin Smolej, L. Lysák, D. Lindtnerová, Michaela Motyčková, M. Vodárek, P. Šimkovič, M.
http://linked.open...ain/vavai/riv/wos	000319143100003
issn	0902-4441
number of pages	7 (xsd:int)
http://bibframe.org/vocab/doi	10.1111/ejh.12106
http://localhost/t...ganizacniJednotka	14740

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software